Boston Scientific Corporation (BSX)
NYSE: BSX · Real-Time Price · USD
49.57
+1.83 (3.83%)
Aug 6, 2026, 1:47 PM EDT - Market open
Boston Scientific Revenue
Boston Scientific had revenue of $5.44B in the quarter ending June 30, 2026, with 7.53% growth. This brings the company's revenue in the last twelve months to $21.00B, up 13.53% year-over-year. In the year 2025, Boston Scientific had annual revenue of $20.07B with 19.87% growth.
Revenue (ttm)
$21.00B
Revenue Growth
+13.53%
P/S Ratio
3.44
Revenue / Employee
$355,864
Employees
59,000
Market Cap
71.84B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 20.07B | 3.33B | 19.87% |
| Dec 31, 2024 | 16.75B | 2.51B | 17.61% |
| Dec 31, 2023 | 14.24B | 1.56B | 12.29% |
| Dec 31, 2022 | 12.68B | 794.00M | 6.68% |
| Dec 31, 2021 | 11.89B | 1.98B | 19.92% |
| Dec 31, 2020 | 9.91B | -822.00M | -7.66% |
| Dec 31, 2019 | 10.74B | 912.00M | 9.28% |
| Dec 31, 2018 | 9.82B | 775.00M | 8.57% |
| Dec 31, 2017 | 9.05B | 662.00M | 7.89% |
| Dec 31, 2016 | 8.39B | 909.00M | 12.16% |
| Dec 31, 2015 | 7.48B | 97.00M | 1.31% |
| Dec 31, 2014 | 7.38B | 237.00M | 3.32% |
| Dec 31, 2013 | 7.14B | -106.00M | -1.46% |
| Dec 31, 2012 | 7.25B | -373.00M | -4.89% |
| Dec 31, 2011 | 7.62B | -184.00M | -2.36% |
| Dec 31, 2010 | 7.81B | -382.00M | -4.67% |
| Dec 31, 2009 | 8.19B | 138.00M | 1.71% |
| Dec 31, 2008 | 8.05B | -307.00M | -3.67% |
| Dec 31, 2007 | 8.36B | 536.00M | 6.85% |
| Dec 31, 2006 | 7.82B | 1.54B | 24.48% |
| Dec 31, 2005 | 6.28B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Abbott Laboratories | 46.59B |
| Medtronic | 36.36B |
| Stryker | 25.84B |
| GE HealthCare Technologies | 21.27B |
| Koninklijke Philips | 20.18B |
| Zimmer Biomet Holdings | 8.51B |
| Edwards Lifesciences | 6.51B |
| Smith & Nephew | 6.30B |
BSX News
- 6 days ago - Argus cuts Boston Scientific to Hold on growth headwinds - TheFly
- 6 days ago - Boston Scientific downgraded to Hold from Buy at Argus - TheFly
- 6 days ago - Penumbra reports Q2 EPS 88c, consensus $1.18 - TheFly
- 6 days ago - Penumbra, Inc. Reports Second Quarter 2026 Financial Results - PRNewsWire
- 7 days ago - Boston Scientific price target lowered to $70 from $85 at RBC Capital - TheFly
- 7 days ago - Boston Scientific price target lowered to $56 from $80 at JPMorgan - TheFly
- 7 days ago - Boston Scientific price target lowered to $54 from $61 at BofA - TheFly
- 7 days ago - Boston Scientific price target lowered to $67 from $74 at UBS - TheFly